Literature DB >> 10545209

Effect of fully sulfated glycosaminoglycans on pulmonary artery smooth muscle cell proliferation.

H G Garg1, P A Joseph, B T Thompson, C A Hales, T Toida, T Imanari, I Capila, R J Linhardt.   

Abstract

Fully sulfated heparin and other glycosaminoglycans, namely heparan, chondroitin, and dermatan sulfates, and hyaluronan have been prepared by using sulfur trioxide under mild chemical conditions. All these derivatives were assayed for antiproliferative activity on cultured bovine pulmonary artery smooth muscle cells (BPASMCs). No appreciable difference was found between heparin and fully sulfated heparin. Chondroitin and dermatan sulfates actually stimulated BPASMCs growth but full sulfonation made them strongly antiproliferative. Native hyaluronan was not antiproliferative but became strongly so after sulfonation. Neither acharan sulfate nor N-sulfoacharan sulfate had any antiproliferative activity. This suggests that O-sulfonation of the polysaccharide is critical for antiproliferative activity, whereas N-sulfonation of glucosamine residues is not. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10545209     DOI: 10.1006/abbi.1999.1456

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  9 in total

Review 1.  Molecular regulation of contractile smooth muscle cell phenotype: implications for vascular tissue engineering.

Authors:  Jeffrey A Beamish; Ping He; Kandice Kottke-Marchant; Roger E Marchant
Journal:  Tissue Eng Part B Rev       Date:  2010-10       Impact factor: 6.389

2.  Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23.

Authors:  Xijie Yu; Omar A Ibrahimi; Regina Goetz; Fuming Zhang; Siobhan I Davis; Holly J Garringer; Robert J Linhardt; David M Ornitz; Moosa Mohammadi; Kenneth E White
Journal:  Endocrinology       Date:  2005-08-04       Impact factor: 4.736

3.  Effect of carboxyl-reduced heparin on the growth inhibition of bovine pulmonary artery smooth muscle cells.

Authors:  Hari G Garg; Hicham Mrabat; Lunyin Yu; Craig Freeman; Boyangzi Li; Fuming Zhang; Robert J Linhardt; Charles A Hales
Journal:  Carbohydr Res       Date:  2010-03-21       Impact factor: 2.104

4.  Increase in the growth inhibition of bovine pulmonary artery smooth muscle cells by an O-hexanoyl low-molecular-weight heparin derivative.

Authors:  Hari G Garg; Charles A Hales; Lunyin Yu; Melissa Butler; Tasneem Islam; Jin Xie; Robert J Linhardt
Journal:  Carbohydr Res       Date:  2006-08-22       Impact factor: 2.104

5.  Anti-proliferative effects of O-acyl-low-molecular-weight heparin derivatives on bovine pulmonary artery smooth muscle cells.

Authors:  Hari G Garg; Hicham Mrabat; Lunyin Yu; Charles A Hales; Boyangzi Li; Casey N Moore; Fuming Zhang; Robert J Linhardt
Journal:  Glycoconj J       Date:  2011-07-20       Impact factor: 2.916

6.  Sulfated hyaluronan derivatives reduce the proliferation rate of primary rat calvarial osteoblasts.

Authors:  Reiner Kunze; Manuela Rösler; Stephanie Möller; Matthias Schnabelrauch; Thomas Riemer; Ute Hempel; Peter Dieter
Journal:  Glycoconj J       Date:  2009-11-26       Impact factor: 2.916

Review 7.  Heparin-binding domains in vascular biology.

Authors:  Eva M Muñoz; Robert J Linhardt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-07-01       Impact factor: 8.311

8.  Significance of the 2-O-sulfo group of L-iduronic acid residues in heparin on the growth inhibition of bovine pulmonary artery smooth muscle cells.

Authors:  Hari G Garg; Hicham Mrabat; Lunyin Yu; Craig Freeman; Boyangzi Li; Fuming Zhang; Robert J Linhardt; Charles A Hales
Journal:  Carbohydr Res       Date:  2008-07-04       Impact factor: 2.104

9.  Acetylation may strengthen the antitumor activity of low molecular heparin.

Authors:  Ying Liang; Guixin Duan; Yuanyuan Wang; Guowen Wang; Ansheng Wang; Kangwu Wang
Journal:  Transl Cancer Res       Date:  2021-01       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.